Coloplast B.V. – Announcement no. 02/2022 – Interim Monetary Report, 9M 2021/2022

9M 2021/22

Interim monetary outcomes, 9M 2021/22

1 October 2021 – 30 June 2022

Coloplast delivered Q3 natural development of 8% and an EBIT margin of 30%. Unchanged monetary steering for FY 2021/22, with natural development at 6-7%, reported development round 15%, and EBIT margin earlier than particular gadgets of round 31%

• Coloplast delivered 8% natural development in Q3. Reported income in DKK was up by 21%. Natural development charges by enterprise space in Q3 had been: Ostomy Care 10%, Continence Care 5%, Interventional Urology 11%, and Wound & Pores and skin Care 5% (Wound Care 4%). Voice & Respiratory Care contributed 9%-points to reported development, with a double-digit underlying development.
• Passable Q3 for Persistent Care, with strong Ostomy Care development throughout all geographies ex. China, which stays impacted by COVID-19. Development in Continence Care was negatively impacted by backorders in Accumulating Gadgets.
• Broad-based development in Interventional Urology, led by the Endourology and the US Males’s Well being companies.
• Contract Manufacturing and the European Wound Care enterprise had been the primary development contributors in Wound & Pores and skin Care.
• EBIT earlier than particular gadgets was DKK 1,761 million, an 11% enhance from final yr. The EBIT margin earlier than particular gadgets was 30% towards 33% final yr, reflecting a normalisation of economic actions and rising prices for power, uncooked supplies, and logistics, in addition to round DKK 57 million in amortisation prices associated to the Atos Medical acquisition.

 9M 2021/22 natural development of seven% and 31% EBIT margin earlier than particular gadgets.

• Coloplast delivered 7% natural development for the primary 9 months of the yr. Reported income in DKK was up by 15% to DKK 16,520 million. Natural development charges by enterprise space had been: Ostomy Care 7%, Continence Care 6%, Interventional Urology 8%, Wound & Pores and skin Care 7% (Wound Care alone 7%). Voice & Respiratory Care contributed 5%-points to the reported development (comprises 5 months of income affect).
• EBIT earlier than particular gadgets amounted to DKK 5,096 million, an 8% enhance from final yr. The EBIT margin earlier than particular gadgets was 31% towards 33% final yr, impacted by round DKK 96 million in amortisation prices associated to the Atos Medical acquisition. EBIT margin after particular gadgets was 28%, impacted by DKK 435 million in particular gadgets¹⁾.
• ROIC after tax earlier than particular gadgets was 26% towards 43% final yr, negatively impacted by the acquisition of Atos Medical. Diluted earnings per share (EPS) earlier than particular gadgets elevated by 4% to DKK 17.90.

 FY 2021/22 monetary steering

• Natural income development continues to be anticipated at 6-7% at fixed alternate charges. Reported development in DKK excluding Atos Medical continues to be anticipated round 9%. The affect of the Atos Medical acquisition on reported development continues to be anticipated to be round 6%-points. In whole, reported development in DKK continues to be anticipated round 15%.
• Reported EBIT margin earlier than particular gadgets continues to be anticipated round 31% and reported EBIT margin after particular gadgets continues to be anticipated at 28-29%, impacted by particular gadgets of round DKK 450 million²⁾.
• Capital expenditures are actually anticipated to be round DKK 1.2 billion. The efficient tax fee continues to be anticipated to be round 23%.

 ”I’m more than happy with our efficiency within the third quarter. We ship 8% natural development and an EBIT margin of 30% and proceed to take market share throughout all our gross sales areas and enterprise areas. Which means we proceed to assist increasingly folks with intimate healthcare wants dwell higher lives. I want to spotlight our sturdy efficiency in Ostomy Care, notably in Europe and the US, in addition to a strong set of development numbers in Interventional Urology and Voice & Respiratory Care. China continues to negatively affect our development in each Ostomy Care and Wound Care resulting from COVID-19 associated restrictions. Outdoors of China, nonetheless, the expansion in new sufferers and the extent of procedures are largely again to pre-COVID ranges,”says President and CEO Kristian Villumsen. 

¹⁾ DKK 300 million provision for prices associated to the US lawsuits alleging harm from the usage of transvaginal surgical mesh merchandise, and DKK 135 million associated to the Atos Medical acquisition.
²⁾ DKK 300 million provision for prices associated to the US lawsuits alleging harm from the usage of transvaginal surgical mesh merchandise. Particular gadgets associated to the Atos Medical acquisition are anticipated to be round DKK 150 million.

Convention name

Coloplast will host a convention name on Wednesday, 17 August 2022 at 15.00 CEST. The decision is predicted to final about one hour.
To actively take part within the Q&A session please name +45 3544 5577, +44 3333 000 804 or +1 631 913 1422. The participant PIN code is 90611412#

Entry the convention name webcast immediately right here:  https://getvisualtv.web/stream/?coloplast-qwigcwkzzn

For additional info, please contact

Traders and analysts
Anders Lonning-Skovgaard
Govt Vice President, CFO
Tel. +45 4911 1111

Aleksandra Dimovska
Director, Investor Relations
Tel. +45 4911 1800 /+45 4911 2458
Electronic mail:  dkadim@coloplast.com

Kristine Husted Munk
Senior Supervisor, Investor Relations
Tel. +45 4911 1800 /+45 4911 3266
Electronic mail: dkkhu@coloplast.com

Press and media
Peter Mønster
Sr. Media Relations Supervisor
Tel. +45 4911 2623
Electronic mail: dkpete@coloplast.com

Deal with
Coloplast A/S
Holtedam 1
DK-3050 Humlebaek
Denmark
Firm reg. (CVR) no. 69749917

Web site
www.coloplast.com

This announcement is accessible in a Danish and an English-language model. Within the occasion of discrepancies, the Danish model shall prevail.

Coloplast develops services and products that make life simpler for folks with very private and personal medical situations. Working intently with the individuals who use our merchandise, we create options which can be delicate to their particular wants. We name this intimate well being care. Our enterprise contains Ostomy Care, Continence Care, Wound & Pores and skin Care, Interventional Urology and Voice & Respiratory Care. We function globally and make use of about 14,00Zero workers.

The Coloplast emblem is a registered trademark of Coloplast A/S. © 2022-08.

All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark.

• 02_2022_9M_Earnings_Release